BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31873779)

  • 1. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy.
    Barelkowski T; Wust P; Kaul D; Zschaeck S; Wlodarczyk W; Budach V; Ghadjar P; Beck M
    Strahlenther Onkol; 2020 Mar; 196(3):229-242. PubMed ID: 31873779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis.
    Tamihardja J; Schortmann M; Lawrenz I; Weick S; Bratengeier K; Flentje M; Guckenberger M; Polat B
    Strahlenther Onkol; 2021 Feb; 197(2):124-132. PubMed ID: 32833036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose escalated fiducial marker-based image guided radical radiotherapy in locally advanced prostate cancers: A single institute experience from India.
    Gupta PK; Rastogi N; Maria Das KJ; Kumar S
    J Cancer Res Ther; 2023; 19(2):382-388. PubMed ID: 37006073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image-guided radiation therapy based on helical tomotherapy in prostate cancer: minimizing toxicity.
    Acevedo-Henao CM; Lopez Guerra JL; Matute R; Puebla F; Russo M; Rivin E; Sanchez-Reyes A; Ortiz MJ; Azinovic I
    Oncol Res Treat; 2014; 37(6):324-30. PubMed ID: 24903763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
    Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.
    Guckenberger M; Ok S; Polat B; Sweeney RA; Flentje M
    Strahlenther Onkol; 2010 Oct; 186(10):535-43. PubMed ID: 20890743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Shimizu D; Yamazaki H; Nishimura T; Aibe N; Okabe H
    Anticancer Res; 2017 Oct; 37(10):5829-5835. PubMed ID: 28982908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
    Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
    Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.
    Cozzi S; Ruggieri MP; Alì E; Ghersi SF; Vigo F; Augugliaro M; Giaccherini L; Iori F; Najafi M; Bardoscia L; Botti A; Trojani V; Ciammella P; Iotti C
    In Vivo; 2023; 37(2):777-785. PubMed ID: 36881094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
    Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S
    Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Outcomes of a Dose-reduction Trial to Decrease Late Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Sasaki N; Yamazaki H; Shimizu D; Suzuki G; Masui K; Nakamura S; Okabe H; Nishikawa T; Yoshida K
    Anticancer Res; 2018 Jan; 38(1):385-391. PubMed ID: 29277799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
    Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 78Gy with Fiducial Marker Image-Guided Radiotherapy in Prostate Cancer: Single Center Analysis of 301 Patients.
    Choong ES; Hruby G; Yang J; Kwong C; Patanjali N
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e356-e363. PubMed ID: 27863019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.
    Nakamura K; Mizowaki T; Inokuchi H; Ikeda I; Inoue T; Kamba T; Ogawa O; Hiraoka M
    Int J Clin Oncol; 2018 Feb; 23(1):158-164. PubMed ID: 28756594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon.
    Deville C; Both S; Bui V; Hwang WT; Tan KS; Schaer M; Tochner Z; Vapiwala N
    Radiat Oncol; 2012 May; 7():76. PubMed ID: 22621764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer.
    Rosenbrock J; Baues C; Kreis M; Fouassi R; Celik E; Paffenholz P; Pfister D; Heidenreich A; Marnitz S
    Strahlenther Onkol; 2023 Jun; 199(6):574-584. PubMed ID: 36930248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.
    Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R
    Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
    Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.